{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:08:18Z","timestamp":1792444098053,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific & Industrial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105446","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T07:46:39Z","timestamp":1634888799000},"page":"105446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model"],"prefix":"10.1016","volume":"117","author":[{"given":"Ganesh","family":"Routholla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Pulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sk.","family":"Abdul Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Bhagavatula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaram","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105446_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2019.05.007","article-title":"Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity","volume":"176","author":"Yun","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/138920208785699580","article-title":"Cause and consequences of genetic and epigenetic alterations in human cancer","volume":"9","author":"Sadikovic","year":"2008","journal-title":"Curr. Genom."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105446_b0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105446_b0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/sj.embor.embor941","article-title":"Regulating histone acetyltransferases and deacetylases","volume":"4","author":"Legube","year":"2003","journal-title":"EMBO Rep."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105446_b0025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer. Inst."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105446_b0030","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105446_b0035","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3390\/ijms20071601","article-title":"Apoptosis induction by histone deacetylase inhibitors in cancer cells: Role of Ku70","volume":"20","author":"Gong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.bioorg.2021.105446_b0040","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","article-title":"Histone deacetylase inhibitors and cell death","volume":"71","author":"Zhang","year":"2014","journal-title":"Cell. Mol. Life. Sci."},{"key":"10.1016\/j.bioorg.2021.105446_b0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ejmech.2018.08.081","article-title":"HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches","volume":"157","author":"Adhikari","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105446_b0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mc.20373","article-title":"HDAC3 overexpression and colon cancer cell proliferation and differentiation","volume":"47","author":"Spurling","year":"2008","journal-title":"Mol. Carcinogen."},{"key":"10.1016\/j.bioorg.2021.105446_b0060","first-page":"663","article-title":"Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer","volume":"5","author":"Ma","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105446_b0065","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Minami","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2021.105446_b0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.08.069","article-title":"Targeting breast cancer stem cells by novel HDAC3-selective inhibitors","volume":"140","author":"Hsieh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105446_b0075","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"HDAC3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2021.105446_b0080","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1021\/acs.jmedchem.0c01676","article-title":"Dissecting HDAC3 in multiple disease conditions: Selective inhibition as a promising therapeutic strategy","volume":"64","author":"Adhikari","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0085","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.12659\/MSM.906576","article-title":"Relationship between histone deacetylase 3 (HDAC3) and breast cancer","volume":"24","author":"Cui","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105446_b0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pan.2019.01.011","article-title":"HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer","volume":"19","author":"Hu","year":"2019","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105446_b0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pros.23467","article-title":"Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer","volume":"78","author":"McLeod","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2021.105446_b0100","first-page":"1305","article-title":"Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer","volume":"52","author":"He","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105446_b0105","doi-asserted-by":"crossref","first-page":"e68915","DOI":"10.1371\/journal.pone.0068915","article-title":"Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma","volume":"8","author":"Wells","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105446_b0110","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/leu.2011.340","article-title":"Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy","volume":"26","author":"Gupta","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105446_b0115","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/leu.2017.144","article-title":"HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications","volume":"31","author":"Harada","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105446_b0120","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1038\/leu.2017.130","article-title":"Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response","volume":"31","author":"Long","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2021.105446_b0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/cas.12684","article-title":"Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase \/ ERK-MMP-laminin5\u03b32 signaling pathway","volume":"106","author":"Liu","year":"2015","journal-title":"Cancer Sci."},{"issue":"49","key":"10.1016\/j.bioorg.2021.105446_b0130","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1038\/sj.onc.1208879","article-title":"Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer","volume":"24","author":"Narita","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105446_b0135","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00109-019-01782-0","article-title":"Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1\/HDAC3\/HSP90 signaling axis","volume":"97","author":"Ma","year":"2019","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bioorg.2021.105446_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.457","article-title":"Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition","volume":"8","author":"Yin","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2021.105446_b0145","doi-asserted-by":"crossref","first-page":"112171","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2021.105446_b0150","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105446_b0155","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105446_b0160","doi-asserted-by":"crossref","first-page":"105274","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: A perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.bioorg.2021.105446_b0165","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm800251w","article-title":"Discovery of N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor","volume":"51","author":"Zhou","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0170","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41598-018-19664-9","article-title":"New 5-Aryl-substituted 2-aminobenzamide-type hdac inhibitors with a diketopiperazine group and their ameliorating effects on ischemia-induced neuronal cell death","volume":"8","author":"Hirata","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105446_b0175","doi-asserted-by":"crossref","first-page":"112291","DOI":"10.1016\/j.ejmech.2020.112291","article-title":"Purine\/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors","volume":"196","author":"Nepali","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2015.05.045","article-title":"Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors","volume":"100","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2021.105446_b0185","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.5b00545","article-title":"Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-Aminophenyl)-benzamide binding unit","volume":"58","author":"Marson","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.03.024","article-title":"Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents","volume":"132","author":"Abdizadeh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105446_b0195","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","article-title":"Entinostat for treatment of solid tumors and hematologic malignancies","volume":"20","author":"Knipstein","year":"2011","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2021.105446_b0200","first-page":"994","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-Acetyldinaline) in the nonhuman primate","volume":"6","author":"Riva","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105446_b0205","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/dom.12470","article-title":"Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats","volume":"17","author":"Lundh","year":"2015","journal-title":"Diabet. Obes. Metab."},{"issue":"43","key":"10.1016\/j.bioorg.2021.105446_b0210","doi-asserted-by":"crossref","first-page":"17598","DOI":"10.1074\/jbc.M117.804328","article-title":"Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes","volume":"292","author":"Dirice","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DDDT.S234871","article-title":"RGFP966 suppresses tumor growth and migration through inhibition of EGFR expression in hepatocellular carcinoma cells in vitro","volume":"14","author":"Yu","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105446_b0220","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1073\/pnas.1213364110","article-title":"HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner","volume":"110","author":"Malvaez","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105446_b0225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105446_b0230","article-title":"Discovery of N-(2-amino-4-fluorophenyl)-4-[bis-(2-chloroethyl)-amino]-benzamide as a potent HDAC3 inhibitor","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2021.105446_b0235","first-page":"1517","article-title":"CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo","volume":"19","author":"Hubeek","year":"2008","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105446_b0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00180810","article-title":"Preclinical antitumor activity of CI-994","volume":"14","author":"LoRusso","year":"1996","journal-title":"Invest. New Drugs."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105446_b0245","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105446_b0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intract. Rare Dis. Res."},{"key":"10.1016\/j.bioorg.2021.105446_b0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejps.2018.08.030","article-title":"Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects","volume":"124","author":"Trivedi","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"23","key":"10.1016\/j.bioorg.2021.105446_b0260","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.1039\/D0NJ01274B","article-title":"Design, synthesis, and biological evaluation of novel nicotinamide derivatives as potential histone deacetylase-3 inhibitors","volume":"44","author":"Hamoud","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejmech.2019.01.077","article-title":"Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides","volume":"166","author":"Amin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105446_b0270","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1080\/07391102.2018.1477625","article-title":"Designing potential HDAC3 inhibitors to improve memory and learning","volume":"37","author":"Amin","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105446_b0275","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acschemneuro.0c00721","article-title":"PT3: A novel benzamide class histone deacetylase 3 inhibitor improves learning and memory in novel object recognition mouse model","volume":"12","author":"Pulya","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2021.105446_b0280","doi-asserted-by":"crossref","first-page":"105050","DOI":"10.1016\/j.bioorg.2021.105050","article-title":"Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors","volume":"114","author":"Routholla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105446_b0285","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of Histone Acetylation: The Histone Deacetylase Enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105446_b0290","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","article-title":"A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors","volume":"96","author":"Saito","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2021.105446_b0295","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood."},{"issue":"7-8","key":"10.1016\/j.bioorg.2021.105446_b0300","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2014The development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"52","key":"10.1016\/j.bioorg.2021.105446_b0305","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.0408345102","article-title":"Apoptotic and autophagic cell death induced by histone deacetylase inhibitors","volume":"101","author":"Shao","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2021.105446_b0310","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1038\/s41598-017-07851-z","article-title":"Luciferase expression allows bioluminescence imaging but imposes limitations on the orthotopic mouse (4T1) model of breast cancer","volume":"7","author":"Baklaushev","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105446_b0315","doi-asserted-by":"crossref","first-page":"e76340","DOI":"10.1371\/journal.pone.0076340","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo","volume":"8","author":"Chiu","year":"2013","journal-title":"PLOS One."},{"key":"10.1016\/j.bioorg.2021.105446_b0320","doi-asserted-by":"crossref","first-page":"20.2.1","DOI":"10.1002\/0471142735.im2002s39","article-title":"Mouse 4T1 breast tumor model","volume":"39","author":"Pulaski","year":"2000","journal-title":"Curr. Protocol. Immunol."},{"key":"10.1016\/j.bioorg.2021.105446_b0325","first-page":"54040","article-title":"An orthotopic mouse model of spontaneous breast cancer metastasis","volume":"114","author":"Paschall","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2021.105446_b0330","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/jcm8111847","article-title":"Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy","volume":"8","author":"Kim","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2021.105446_b0335","first-page":"1210","article-title":"In vivo bioluminescent imaging of mammary tumors using IVIS spectrum","volume":"26","author":"Lim","year":"2009","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2021.105446_b0340","unstructured":"Schr\u00e7dinger Suite, Schr\u00e7dinger, LLC, New York, USA, 2019. http:\/\/www.schrodinger.com\/glide., n.d."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:25:36Z","timestamp":1758615936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821008233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":68,"alternative-id":["S0045206821008233"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105446","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105446"}}